Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
_NotFinancialAdvice_
_NotFinancialAdvice_ May. 12 at 8:12 PM
$PPCB day 4 of up to 10 under 10¢.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 12 at 3:11 AM
$PPCB RSI: 29.96, MACD: -0.0085 Vol: 0.01, MA20: 0.11, MA50: 0.12 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 11 at 1:39 PM
$PPCB We believe the long-term opportunity for Propanc extends beyond a single indication. While pancreatic cancer remains a key initial focus, our broader strategy is centered around developing PRP as a platform targeting recurrence, metastasis, resistant tumors, and the biological drivers that allow cancer to spread. PRP previously received FDA Orphan Drug Designation for pancreatic cancer, supporting the significance of the unmet need in this space. Earlier compassionate use findings published in Scientific Reports also provided encouraging observations in terminal pancreatic cancer patients, with survival outcomes exceeding expectations and no severe or serious side effects reported during treatment. Looking ahead, our roadmap already extends beyond the planned Phase 1b study. Following completion of the First-In-Human trial, we intend to pursue Phase 2 studies in both pancreatic and ovarian cancers to establish proof of concept across multiple indications.
1 · Reply
_NotFinancialAdvice_
_NotFinancialAdvice_ May. 8 at 12:59 PM
$PPCB there is practically nothing left to short, and the 10 days under 10¢ countdown has now started. The smell of OTC is in the air.
1 · Reply
ka1954
ka1954 May. 8 at 10:52 AM
$PPCB only if the stock doesn't get slaughtered by the shorts.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 7 at 1:43 PM
$PPCB We continue advancing toward a major milestone for Propanc with the planned filing of a Clinical Trial Application (CTA) in Australia later this year for our Phase 1b First-In-Human study of PRP. The trial is expected to enroll approximately 30–40 advanced cancer patients suffering from solid tumors and represents the transition of PRP from years of preclinical development into the clinical stage. Key preparation activities are already underway, including GMP manufacturing, pharmacokinetics assay validation through our collaboration with FyoniBio, and regulatory work required ahead of trial initiation. The study is designed around an intravenous formulation of PRP administered at significantly higher doses than earlier compassionate use experience, supported by non-clinical safety and tolerability data. Each operational milestone helps strengthen readiness for the clinic while positioning Propanc to begin generating human data in areas where treatment outcomes remain limited.
0 · Reply
Dieseld28
Dieseld28 May. 7 at 10:55 AM
$ASBP $PPCB
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 6 at 5:35 PM
$PPCB Pancreatic cancer field is beginning to show signs of real momentum. New research across oncology continues reinforcing the importance of targeting not only tumors themselves, but also the biological mechanisms tied to resistance, recurrence, and metastasis. We believe this broader shift is important for Propanc because PRP was designed around that same understanding of cancer biology. Our lead asset is being developed to target cancer stem cells and processes associated with tumor spread, areas receiving growing attention as the industry searches for more durable treatment strategies. At the same time, pancreatic cancer continues to represent one of the largest unmet needs in oncology, with global treatment markets expected to expand substantially over the coming decade as demand for better therapies increases.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 4 at 1:45 PM
$PPCB Pancreatic cancer remains one of the highest unmet need areas in oncology, with survival still measured in low double digits and limited meaningful improvement over time. At the same time, it represents a multi-billion-dollar global market that continues to expand as demand grows for therapies that can move beyond marginal benefit. This imbalance is what makes the space structurally important. When outcomes are poor and options are limited, even incremental biological improvements can reshape how therapies are positioned and how the market assigns long-term value. PRP is being developed into this environment, targeting recurrence and metastasis at a foundational level through a multi-mechanism approach. For Propanc, execution is the turning point. If early clinical data supports the approach, the company shifts from development story to potential re-rating candidate, and the long-term vision starts to become materially relevant.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 1 at 2:45 PM
$PPCB In pancreatic cancer, the challenge has never been initial response, but durability. That’s why preclinical results around PRP are being closely followed. In models, the therapy has shown >85% tumor growth inhibition, along with activity on mechanisms linked to metastasis and recurrence, including cancer stem cell pathways and tumor microenvironment regulation. Furthermore, compassionate use data published in Scientific Reports, an online Nature journal, using a once daily suppository of trypsinogen and chymotrypsinogen in a fixed combination of 8.92mg ea., resulted in 3 out of 4 patients significantly exceeding life expectancy for terminal pancreatic cancer with no severe, or even serious side effects observed from treatment (2017).
1 · Reply
Latest News on PPCB
Propanc Biopharma files to sell 15M shares of common stock for holders

2026-04-10T21:35:15.000Z - 4 weeks ago

Propanc Biopharma files to sell 15M shares of common stock for holders

Propanc Biopharma signs multi-year collaboration with Spanish universities

2026-03-24T13:11:19.000Z - 7 weeks ago

Propanc Biopharma signs multi-year collaboration with Spanish universities

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Mar 24, 2026, 8:45 AM EDT - 7 weeks ago

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Propanc Biopharma announces highlights of PRP

2026-03-12T13:04:12.000Z - 2 months ago

Propanc Biopharma announces highlights of PRP

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Mar 12, 2026, 8:45 AM EDT - 2 months ago

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Propanc Biopharma executes service agreement with FyoniBio

2026-03-10T12:51:18.000Z - 2 months ago

Propanc Biopharma executes service agreement with FyoniBio

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Mar 10, 2026, 8:45 AM EDT - 2 months ago

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Propanc Biopharma highlights potential of lead asset PRP

2026-03-03T13:59:37.000Z - 2 months ago

Propanc Biopharma highlights potential of lead asset PRP

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Mar 3, 2026, 8:45 AM EST - 2 months ago

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma provides corporate update

2026-02-18T13:50:25.000Z - 3 months ago

Propanc Biopharma provides corporate update

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Feb 18, 2026, 8:45 AM EST - 3 months ago

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma highlights potential of lead proenzyme therapy

2026-02-05T13:50:26.000Z - 3 months ago

Propanc Biopharma highlights potential of lead proenzyme therapy

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Feb 5, 2026, 8:45 AM EST - 3 months ago

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma files to sell 7M shares of common stock for holders

2026-02-02T22:35:25.000Z - 3 months ago

Propanc Biopharma files to sell 7M shares of common stock for holders

Propanc Biopharma files fourth patent application with IP Australia

2026-01-27T13:50:56.000Z - 3 months ago

Propanc Biopharma files fourth patent application with IP Australia

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Jan 27, 2026, 8:45 AM EST - 3 months ago

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma files new provisional patent application with IP Australia

2026-01-20T13:56:58.000Z - 4 months ago

Propanc Biopharma files new provisional patent application with IP Australia

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Jan 20, 2026, 8:45 AM EST - 4 months ago

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma announces update on pancreatic cancer research

2026-01-15T13:50:32.000Z - 4 months ago

Propanc Biopharma announces update on pancreatic cancer research

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Jan 15, 2026, 8:45 AM EST - 4 months ago

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma issues letter to shareholders

2026-01-13T13:56:11.000Z - 4 months ago

Propanc Biopharma issues letter to shareholders

Propanc Biopharma Provides Shareholder Update

Jan 13, 2026, 8:45 AM EST - 4 months ago

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma publishes impact of proenzymes on PDAC fibroblasts

2025-12-22T12:05:46.000Z - 5 months ago

Propanc Biopharma publishes impact of proenzymes on PDAC fibroblasts

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22, 2025, 7:00 AM EST - 5 months ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma plans to investigate ‘mesenchymal drift’

2025-12-04T13:50:28.000Z - 5 months ago

Propanc Biopharma plans to investigate ‘mesenchymal drift’

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 4, 2025, 8:45 AM EST - 5 months ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma requests foreign filing license from Spain

2025-12-01T13:50:30.000Z - 5 months ago

Propanc Biopharma requests foreign filing license from Spain

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Dec 1, 2025, 8:45 AM EST - 5 months ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma reports Q1 EPS (39c) vs. ($35.97) last year

2025-11-17T13:50:07.000Z - 6 months ago

Propanc Biopharma reports Q1 EPS (39c) vs. ($35.97) last year

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 17, 2025, 8:45 AM EST - 6 months ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma enters securities purchase agreement with Hexstone

2025-11-10T13:51:25.000Z - 6 months ago

Propanc Biopharma enters securities purchase agreement with Hexstone

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 10, 2025, 8:45 AM EST - 6 months ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Propanc Biopharma announces initiative to pursue acquisition of DAT

2025-11-04T12:40:14.000Z - 6 months ago

Propanc Biopharma announces initiative to pursue acquisition of DAT

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Nov 4, 2025, 7:00 AM EST - 6 months ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 5:45 PM EDT - 7 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma announces financing agreement up to $100M

2025-10-15T12:50:41.000Z - 7 months ago

Propanc Biopharma announces financing agreement up to $100M

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 7 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma reports total assets of $19.6M as of June 30

2025-10-07T12:55:35.000Z - 7 months ago

Propanc Biopharma reports total assets of $19.6M as of June 30

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Oct 7, 2025, 8:45 AM EDT - 7 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 17, 2025, 8:45 AM EDT - 8 months ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Sep 2, 2025, 9:00 AM EDT - 9 months ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 9 months ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 9 months ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

_NotFinancialAdvice_
_NotFinancialAdvice_ May. 12 at 8:12 PM
$PPCB day 4 of up to 10 under 10¢.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 12 at 3:11 AM
$PPCB RSI: 29.96, MACD: -0.0085 Vol: 0.01, MA20: 0.11, MA50: 0.12 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 11 at 1:39 PM
$PPCB We believe the long-term opportunity for Propanc extends beyond a single indication. While pancreatic cancer remains a key initial focus, our broader strategy is centered around developing PRP as a platform targeting recurrence, metastasis, resistant tumors, and the biological drivers that allow cancer to spread. PRP previously received FDA Orphan Drug Designation for pancreatic cancer, supporting the significance of the unmet need in this space. Earlier compassionate use findings published in Scientific Reports also provided encouraging observations in terminal pancreatic cancer patients, with survival outcomes exceeding expectations and no severe or serious side effects reported during treatment. Looking ahead, our roadmap already extends beyond the planned Phase 1b study. Following completion of the First-In-Human trial, we intend to pursue Phase 2 studies in both pancreatic and ovarian cancers to establish proof of concept across multiple indications.
1 · Reply
_NotFinancialAdvice_
_NotFinancialAdvice_ May. 8 at 12:59 PM
$PPCB there is practically nothing left to short, and the 10 days under 10¢ countdown has now started. The smell of OTC is in the air.
1 · Reply
ka1954
ka1954 May. 8 at 10:52 AM
$PPCB only if the stock doesn't get slaughtered by the shorts.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 7 at 1:43 PM
$PPCB We continue advancing toward a major milestone for Propanc with the planned filing of a Clinical Trial Application (CTA) in Australia later this year for our Phase 1b First-In-Human study of PRP. The trial is expected to enroll approximately 30–40 advanced cancer patients suffering from solid tumors and represents the transition of PRP from years of preclinical development into the clinical stage. Key preparation activities are already underway, including GMP manufacturing, pharmacokinetics assay validation through our collaboration with FyoniBio, and regulatory work required ahead of trial initiation. The study is designed around an intravenous formulation of PRP administered at significantly higher doses than earlier compassionate use experience, supported by non-clinical safety and tolerability data. Each operational milestone helps strengthen readiness for the clinic while positioning Propanc to begin generating human data in areas where treatment outcomes remain limited.
0 · Reply
Dieseld28
Dieseld28 May. 7 at 10:55 AM
$ASBP $PPCB
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 6 at 5:35 PM
$PPCB Pancreatic cancer field is beginning to show signs of real momentum. New research across oncology continues reinforcing the importance of targeting not only tumors themselves, but also the biological mechanisms tied to resistance, recurrence, and metastasis. We believe this broader shift is important for Propanc because PRP was designed around that same understanding of cancer biology. Our lead asset is being developed to target cancer stem cells and processes associated with tumor spread, areas receiving growing attention as the industry searches for more durable treatment strategies. At the same time, pancreatic cancer continues to represent one of the largest unmet needs in oncology, with global treatment markets expected to expand substantially over the coming decade as demand for better therapies increases.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 4 at 1:45 PM
$PPCB Pancreatic cancer remains one of the highest unmet need areas in oncology, with survival still measured in low double digits and limited meaningful improvement over time. At the same time, it represents a multi-billion-dollar global market that continues to expand as demand grows for therapies that can move beyond marginal benefit. This imbalance is what makes the space structurally important. When outcomes are poor and options are limited, even incremental biological improvements can reshape how therapies are positioned and how the market assigns long-term value. PRP is being developed into this environment, targeting recurrence and metastasis at a foundational level through a multi-mechanism approach. For Propanc, execution is the turning point. If early clinical data supports the approach, the company shifts from development story to potential re-rating candidate, and the long-term vision starts to become materially relevant.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma May. 1 at 2:45 PM
$PPCB In pancreatic cancer, the challenge has never been initial response, but durability. That’s why preclinical results around PRP are being closely followed. In models, the therapy has shown >85% tumor growth inhibition, along with activity on mechanisms linked to metastasis and recurrence, including cancer stem cell pathways and tumor microenvironment regulation. Furthermore, compassionate use data published in Scientific Reports, an online Nature journal, using a once daily suppository of trypsinogen and chymotrypsinogen in a fixed combination of 8.92mg ea., resulted in 3 out of 4 patients significantly exceeding life expectancy for terminal pancreatic cancer with no severe, or even serious side effects observed from treatment (2017).
1 · Reply
PaulLaurent
PaulLaurent Apr. 30 at 3:38 PM
🔄📉 Oversold Small Caps Update 🧪🔄 $CHSN $INHD $LZMH $MEHA $PPCB
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Apr. 30 at 1:56 PM
$PPCB We are entering a stage where preparation is turning into execution. The collaboration with FyoniBio to validate a pharmacokinetics assay is part of the infrastructure needed for our Phase 1b study, designed to measure how PRP behaves in patients once dosing begins. Alongside GMP manufacturing and regulatory work, these steps are converging toward the same point: initiating a clinical trial application for first-in-human testing in 2026. What matters here is the shift in state. The company is no longer only building the science, it is building the system required to test that science in a clinical environment. For Propanc, this is where long development cycles start to compress into measurable milestones. The focus now is execution toward the clinic, and the ability to convert preparation into real patient data will define the next phase of the story.
0 · Reply
asavasir
asavasir Apr. 30 at 1:02 PM
$PPCB keep your 2 cents in, never know this kind of stock may climb 1000X within days
0 · Reply
Has_entered_the_chat
Has_entered_the_chat Apr. 29 at 6:46 PM
$PPCB prison has been rough on me butt...im happy to be back. What i miss?
0 · Reply
Has_entered_the_chat
Has_entered_the_chat Apr. 29 at 6:43 PM
$PPCB
0 · Reply
q3qd
q3qd Apr. 28 at 2:50 PM
$PPCB Holding a few shares because you never know with biotech stocks.
0 · Reply
Rclamdig
Rclamdig Apr. 27 at 1:05 PM
$PPCB
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Apr. 24 at 1:37 PM
$PPCB Our latest research agreement with the Universities of Jaén and Granada reflects how PRP is being developed as more than a single-use therapy. This long-standing collaboration has already contributed to multiple patent families and publications. The new phase will explore additional applications, including fibrosis and senescence-related pathways. This matters because it broadens how the platform could be positioned over time. While pancreatic cancer remains a primary focus, the same underlying mechanisms may apply to other high-need conditions. At the same time, recent patent activity continues strengthening protection, with the potential to significantly expand global IP coverage. As Propanc moves toward clinical development, the strategy combines depth in one indication with optionality across others. The focus remains on advancing PRP while continuing to build long-term value through science and intellectual property.
0 · Reply
Rclamdig
Rclamdig Apr. 24 at 12:47 PM
$PPCB
0 · Reply
PureTrades
PureTrades Apr. 23 at 7:17 PM
$CTNT $PPCB $SBEV Three top picks for after hours along with SHFS for massive upswing. ⏳⏳⏳⏳⏳⚡️⚡️⚡️⚡️⚡️⚡️⚡️⚡️
1 · Reply
WuTangMane
WuTangMane Apr. 23 at 3:32 PM
$PPCB very intresting im in. $BURU $AIXI $CXAI my main babys
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Apr. 23 at 1:51 PM
$PPCB As we move closer to human trials, a lot of the work happens behind the scenes. Our agreement with FyoniBio is a good example. Together, we are developing and validating a pharmacokinetics assay designed to track how PRP behaves in the body during the upcoming Phase 1b study. That includes measuring concentration levels over time and supporting safety and tolerability analysis. This kind of infrastructure is what turns a therapy from concept into something testable in patients. It sits alongside other key steps already underway, including GMP manufacturing and regulatory preparation. With this foundation coming together, Propanc continues aligning the pieces required for first-in-human data. The focus now is on execution and readiness, with each step reducing uncertainty around trial initiation.
0 · Reply